{
  "docId": "019dd923-622c-750b-8b9b-8e8b0729eceb",
  "docSlug": "8a1ba1db7307",
  "documentTitle": "Pershing Square Portfolio (multi-position annual update)",
  "authorId": "01_Pershing_Square",
  "authorName": "Pershing Square Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2015-01-29 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 24,
  "pageCount": 81,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "thesis_headline",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-8e8b0729eceb/24",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-8e8b0729eceb",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-8e8b0729eceb.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-8e8b0729eceb#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.065,
        "w": 0.914,
        "x": 0.043,
        "y": 0.0073
      },
      "kind": "callout",
      "text": "Limited downside",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e03ad678-b5f1-4e2c-a92e-bf892f8d4882",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.914,
        "x": 0.043,
        "y": 0.00185
      },
      "kind": "callout",
      "text": "Strategic rationale of a Valeant/Allergan merger",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6c0bd24-f5d6-46ad-8932-4ded8aab4f8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "Given the strategic overlap between Valeant and Allergan’s product portfolios and Valeant’s superior cost structure, operating model and capital allocation strategy, we believed a merger between Valeant and Allergan had the potential to create enormous shareholder value",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-1ac1-76e9-bcdb-f75d59d23e60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.886,
        "x": 0.071,
        "y": 0.00265
      },
      "kind": "list",
      "text": "Allergan has a strong track record of organic growth driven by a portfolio of market leading products, including the fast-growing Botox franchise\nAllergan has a poor track record of capital allocation and cost management\nGiven the strategic overlap between Valeant and Allergan’s product portfolios and Valeant’s superior cost structure, operating model and capital allocation strategy, we believed a merger between Valeant and Allergan had the potential to create enormous shareholder value",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22e07c4b-4ed6-4853-9ce0-e075b4c4c131",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.886,
        "x": 0.071,
        "y": 0.0081
      },
      "kind": "list",
      "text": "We invested in Allergan at a valuation that reflected the fair value of the business, assuming no improvements in operations or a transaction",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ec10275-b3b1-410f-adfc-8a00c124acc6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.054,
        "w": 0.536,
        "x": 0.036,
        "y": 0.078
      },
      "kind": "title",
      "text": "Allergan Investment Thesis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9e076e0-bb03-4a81-8a48-3ab0f9570ed2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Thesis archetype",
      "slug": "thesis-archetype",
      "agent": null,
      "layer": "slide",
      "matchId": "5f981a63-73fe-4426-b89b-930c34e20ca3",
      "evidence": "callout/primary: Strategic rationale of a Valeant/Allergan merger",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "capital-allocation-framework",
      "slug": null,
      "matchId": "9195a7f1-fb73-4739-8335-970d54220b4f",
      "evidence": "Mentions capital allocation strategy and cost management as key drivers for merger value.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 81,
      "from": 21,
      "beatId": "ca908ed6-09de-4041-87d4-d25c486e2e39",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "Detailed portfolio company updates and performance data",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}